Introduction
The prognosis of inoperable adrenal carcinoma has altered since the introduction of 1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)-ethane-o,p'-DDD-which has been demonstrated to have a cytotoxic action on the adrenal cortex (Vilar and Tullner, 1959) . Its use has been limited by the high incidence of toxic effects on the gastrointestinal tract and central nervous system (Hutter and Kayhoe, 1966b; Bergenstal et al., 1960) . Aminoglutethimide has no cytotoxic activity but reduces output of active steroids by inhibiting the enzymatic production of the precursor pregnenolone (Cash et al., 1967) . It might therefore be expected that the actions of o,p'-DDD and aminoglutethimide would be complementary but their combined use appears to have been reported previously in only a single case of metastatic adrenal carcinoma (Bochner et al., 1969 
Discussion
This patient's prognosis was poor from the time he was first seen because he had high urinary steroid levels and because metastases were evident (Hutter and Kayhoe, 1966a ; Thorn and Lauler, 1972) . That he survived for 2 years after the discovery of functional metastases and was able to work for part of this time might be attributed to the use of o,p'-DDD and aminoglutethimide. His failure to respond to radiotherapy is in accordance with published experience (Hutter and Kayhoe, 1966b ; Thorn and Lauler, 1972) .
O,p'-DDD was poorly tolerated in this patient although the symptoms of gastro-intestinal and central nervous system dysfunction did not differ from those usually encountered (Hutter and Kayhoe, 1966b ). The maximum reduction in steroid levels was achieved with a daily dose of 9 g supporting the suggestion that 10 g daily is the optimum dose (Cope, 1972; Geyer, 1967 Aminoglutethimide in the conventional dose of 1 g daily was well tolerated and at autopsy the thyroid gland was normal, in contrast to the occasional finding of goitre (Rallison, Kumagai and Tyler, 1967) . After the introduction of aminoglutethimide, steroid excretion did not fall rapidly (Philbert et al., 1966) , apart from the slight predictable decline in urinary 17-OHCS excretion (Fishman et al., 1967; Schteingart and Conn, 1967) . It is possible, however, that there was a rapid decline in steroid production after the withdrawal of betamethasone.
This experience suggests that replacement therapy with corticosteroids should be maintained throughout treatment with aminoglutethimide for adrenal carcinoma. A similar recommendation has also been made for patients receiving o,p'-DDD (Helson, Wollner and Murphy, 1971) , although it has also been suggested that the combination of steroid replacement therapy with o,p'-DDD may not be necessary (Temple et al., 1969 
